by Alex C. Spyropoulos, and James D. Douketis

Slides:



Advertisements
Similar presentations
Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.
Advertisements

Evidence-Based Management of Anticoagulant Therapy
Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.
DURNER L.,BOURDOUMIS A., MASOOD J., BUCHHOLZ N. ROYAL LONDON HOSPITAL, BARTSHEALTH NHS TRUST ROYAL DEVON AND EXETER NHS TRUST HOMERTON UNIVERSITIY HOSPITAL.
To Bridge or Not to Bridge: Guide to Clinicians Hazem Elewa, RPh, PhD, BCPS Assistant Professor, College of Pharmacy, Qatar University.
Bridge Therapy: Peri-operative Anticoagulation Management Amjad AlMahameed, MD, MPH Division of Cardiology Beth Israel Deaconess Medical Center Boston.
Question: How should we manage periprocedural anticoagulation? Paper: Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures Todd.
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Study Guide Guide for Patients Undergoing Anticoagulant Therapy.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
LIFEBLOOD THE Thrombosis CHARITY LIFEBLOOD THE Thrombosis CHARITY NICE Clinical Guideline 46.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin mg/d Prophylactic LMWH Therapeutic.
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Nathan P. Clark, Pharm D, FCCP, BCPS Clinical Pharmacy Supervisor Clinical Pharmacy Anticoagulation and Anemia Service Kaiser Permanente Colorado Aurora,
Prevention of Venous Thromboembolism in Nonsurgical Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
G UIDELINES FOR THE P ERI -P ROCEDURAL M ANAGEMENT OF A DULTS T AKING T ARGET S PECIFIC A NTICOAGULANTS (TSOAC S ): DABIGATRAN, RIVAROXABAN, APIXABAN,
Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.
1 MMM October 2008 AVAIL ME Project Audit of Venous Thromboembolism Management in Middle East Hospitals Elham Mir,MD MPH Medical Affairs Clinical Operation.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Prevention of Venous Thromboembolism in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
How I treat recurrent deep-vein thrombosis by Paul A. Kyrle Blood Volume 127(6): February 11, 2016 ©2016 by American Society of Hematology.
Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας Διαχείριση αντιπηκτικής αγωγής εν όψει προγραμματισμένων επεμβατικών πράξεων.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Evidence-Based Management of Anticoagulant Therapy
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
Anticoagulation Prepared by Cherie Gan.
by Nadine Martel, James Lee, and Philip S. Wells
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
by James O. Armitage, and Dan L. Longo
Hepatitis C in the rituximab era
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
A Better Solution For Cancer Patients With VTE?
New oral anticoagulants—what the cardiothoracic surgeon needs to know
Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer 
Blocking VWF platelet binding to treat TTP
Don't look now! Risk stratify first
Succinct Review of the New VTE Prevention and Management Guidelines
Cancer-Associated Thrombosis
Bridging Anticoagulation
James L. Cox, MD, Niv Ad, MD, Terry Palazzo, RN, MS 
The Journal of Thoracic and Cardiovascular Surgery
NOAC Studies in VTE AF Studies Superior Outcomes.
How I treat cancer-associated venous thromboembolism
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
Thrombophilia in pregnancy: Whom to screen, when to treat
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
(p for noninferiority = 0.01)
Reply Journal of Vascular Surgery
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens by Johannes Oldenburg Blood Volume 125(13):
Presentation transcript:

by Alex C. Spyropoulos, and James D. Douketis How I treat anticoagulated patients undergoing an elective procedure or surgery by Alex C. Spyropoulos, and James D. Douketis Blood Volume 120(15):2954-2962 October 11, 2012 ©2012 by American Society of Hematology

Suggested periprocedural heparin bridging strategies for patients on chronic VKA based on patient thromboembolic and procedural bleed risk. Suggested periprocedural heparin bridging strategies for patients on chronic VKA based on patient thromboembolic and procedural bleed risk. Data from the 9th edition ACCP Guidelines: all grade 2C, except intermediate TE risk.7 *For high-bleed risk procedures: wait a full 48-72 hours before reinitiating postprocedural heparin (LMWH) bridging (especially treatment dose); stepwise increase in postprocedural heparin (LMWH) dose from prophylactic dose first 24-48 hours to intermediate/treatment dose; no postprocedural heparin (LMWH) bridging in very high bleed risk procedures (ie, major neurosurgical or cardiovascular surgeries) but use of mechanical prophylaxis. **Based on individual patient- and procedural-related risk factors for thrombosis and bleeding. Alex C. Spyropoulos, and James D. Douketis Blood 2012;120:2954-2962 ©2012 by American Society of Hematology